Search

Your search keyword '"Shiga, Tohru"' showing total 339 results
Start Over Author "Shiga, Tohru" Search Limiters Peer Reviewed
339 results on '"Shiga, Tohru"'

2. An open-label, single-arm, multi-center, phase II clinical trial of single-dose [131I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma

Author

Inaki, Anri, Shiga, Tohru, Tsushima, Yoshito, Jinguji, Megumi, Wakabayashi, Hiroshi, Kayano, Daiki, Akatani, Norihito, Yamase, Takafumi, Kunita, Yuji, Watanabe, Satoru, Hiromasa, Tomo, Mori, Hiroshi, Hirata, Kenji, Watanabe, Shiro, Higuchi, Tetsuya, Tomonaga, Hiroyasu, and Kinuya, Seigo

Published
2022
Full Text
View/download PDF

12. Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.

Author

Kobayakawa, Masao, Shiga, Tohru, Takahashi, Kazuhiro, Sugawara, Shigeyasu, Nomura, Kaori, Hanada, Kazuhiko, Ishizuka, Naoki, and Ito, Hiroshi

Subjects
*PARAGANGLIOMA, *PHEOCHROMOCYTOMA, *PROGRESSION-free survival, *CHROMAFFIN cells, *RESEARCH protocols, *PHARMACOKINETICS
Abstract

Background: Pheochromocytoma, or paraganglioma (PPGL), is a tumor that arises from catecholamine-producing chromaffin cells of the adrenal medulla or paraganglion. Systemic therapy, such as the combination of cyclophosphamide, vincristine, and dacarbazine or therapeutic radiopharmaceuticals such as [131I] meta-iodobenzylguanidine (MIBG), may be administered in cases of locally advanced tumors or distant metastases. However, the current therapies are limited in terms of efficacy and implementation. [211At] meta-astatobenzylguanidine (MABG) is an alpha-emitting radionuclide-labeled ligand that has demonstrated remarkable tumor-reducing effects in preclinical studies, and is expected to have a high therapeutic effect on pheochromocytoma cells. Methods: We are currently conducting an investigator-initiated first-in-human clinical trial to evaluate the pharmacokinetics, safety, and efficacy of [211At] MABG. Patients with locally unresectable or metastatic PPGL refractory to standard therapy and scintigraphically positive [123I] MIBG aggregation are being recruited, and a 3 + 3 dose escalation design was adopted. The initial dose of [211At] MABG is 0.65 MBq/kg, with a dose escalation in a 1:2:4 ratio in each cohort. Dose-limiting toxicity is observed for 6 weeks after a single bolus dose of [211At] MABG, and the patients are observed for 3 months to explore safety and efficacy profiles. The primary endpoint is dose-limiting toxicity to determine both maximum tolerated and recommended doses. The secondary endpoints include radiopharmacokinetics, urinary radioactive excretion rate, urinary catecholamine response rate, objective response rate, progression free survival, [123I] MIBG scintigraphy on reducing tumor accumulation, and quality of life. Trials registration: jRCT2021220012 registered on 17 June 2022. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Impact of patient characteristic factors on the dynamics of liver glucose metabolism: Evaluation of multiparametric imaging with dynamic whole‐body 18F‐fluorodeoxyglucose‐positron emission tomography.

Author

Tonda, Kai, Iwabuchi, Yu, Shiga, Tohru, Owaki, Yoshiki, Fujita, Arashi, Nakahara, Takehiro, Sakurai, Ryosuke, Shimizu, Atsushi, Yamada, Yoshitake, Okada, Masahiro, and Jinzaki, Masahiro

Subjects
GLUCOSE metabolism, LEAN body mass, POSITRON emission tomography, BODY mass index, MULTIPLE regression analysis, GLYCOSYLATED hemoglobin
Abstract

Aims: To assess the impact of various patient characteristics on the dynamics of liver glucose metabolism using automated multiparametric imaging with whole‐body dynamic 18F‐fluorodeoxyglucose (FDG)‐positron emission tomography (PET). Materials and Methods: We retrospectively enrolled 540 patients who underwent whole‐body dynamic FDG‐PET. Three quantitative indices representing hepatic glucose metabolism [mean standardized uptake value normalized by lean body mass (SULmean), metabolic glucose rate (kinetic index) and distribution volume (DV)] were measured from multiparametric PET images produced automatically based on the Patlak plot model. Patient characteristics including age, sex, body mass index, fasting time, blood glucose level, and the presence of diabetes mellitus (DM) or hepatic steatosis (HS) were collected. We examined the correlations between the characteristic factors and three quantitative indices using multiple regression analysis. Results: The success rate of kinetic analysis using multiparametric PET imaging was 93.3% (504/540). Hepatic SULmean was significantly correlated with age (p <.001), sex (p <.001) and blood glucose level (p =.002). DV was significantly correlated with age (p =.033), sex (p <.001), body mass index (p =.002), fasting time (p =.043) and the presence of HS (p =.002). The kinetic index was significantly correlated with age (p <.001) and sex (p =.004). In the comparison of the healthy, DM and HS groups, patients with DM had a significantly increased SULmean, whereas patients with HS had a significantly decreased DV. Conclusions: Our results showed that liver glucose metabolism was influenced by various patient characteristic factors. Multiparametric FDG‐PET imaging can be used to analyse the kinetics of liver glucose metabolism in routine clinical practice. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results